Charles Gorey, DO
Family Medicine · Royersford, PANPI 1194769596
Payments from drug & device makers
Across 401 payments — averaging $16.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$733
- AbbVie$703
- Lilly USA, LLC$486
- GSK$380
- Amgen$342
- plus $3K from 25 others
What the payments were for
- Food & beverage$6,527100%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 61 | $1,194 |
| Novo Nordisk | 46 | $733 |
| AbbVie(2 entities) | 42 | $703 |
| Lilly USA, LLC | 29 | $486 |
| GSK | 21 | $380 |
| Amgen(2 entities) | 21 | $342 |
| Pfizer | 37 | $294 |
| Boehringer Ingelheim | 16 | $280 |
| Abbott | 11 | $242 |
| Merck | 22 | $225 |
| Amarin Pharma, Inc. | 22 | $204 |
| Bayer | 6 | $191 |
| Novartis | 9 | $184 |
| Astellas Pharma US Inc | 6 | $147 |
| Sanofi-aventis U.S. LLC | 11 | $144 |
| Exact Sciences | 5 | $128 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $114 |
| Lundbeck LLC | 4 | $90 |
| Phathom Pharmaceuticals, Inc. | 5 | $86 |
| Otsuka America Pharmaceutical, Inc. | 3 | $70 |
| Sanofi Pasteur Inc. | 4 | $60 |
| Kowa Pharmaceuticals America, Inc. | 4 | $54 |
| Tolmar, Inc. | 2 | $33 |
| Shire North American Group Inc | 2 | $31 |
| Insulet Corporation | 1 | $25 |
| Supernus Pharmaceuticals, Inc. | 1 | $24 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Theracosbio, LLC | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Metuchen Pharmaceuticals | 1 | $11 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,548 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 244 | $173,642 |
| EliquisApixaban | 200 | $156,421 |
| OzempicSemaglutide | 99 | $133,368 |
| MounjaroTirzepatide | 80 | $84,068 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 76 | $66,575 |
| XareltoRivaroxaban | 100 | $65,144 |
| TrulicityDulaglutide | 50 | $61,563 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 40 | $45,070 |
| Invega SustennaPaliperidone Palmitate | 12 | $44,398 |
| XifaxanRifaximin | 24 | $42,976 |
| FarxigaDapagliflozin Propanediol | 54 | $35,890 |
| Xigduo XrDapaglifloz Propaned/Metformin | 18 | $29,221 |
| SynjardyEmpagliflozin/Metformin Hcl | 34 | $26,792 |
| JanuviaSitagliptin Phosphate | 41 | $25,860 |
| LinzessLinaclotide | 27 | $22,575 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Spiriva Respimat, Combivent Respimat | $280 | $267,264353 claims |
| PfizerEliquis | $294 | $156,421200 claims |
| Lilly USA, LLCMounjaro, Trulicity | $486 | $145,631130 claims |
| Novo NordiskOzempic, Rybelsus | $733 | $144,891111 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $380 | $88,889116 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $114 | $42,97624 claims |
| AstraZenecaFarxiga | $1,194 | $35,89054 claims |
| MerckJanuvia, Janumet | $225 | $35,38769 claims |
| AbbVieLinzess, Restasis | $703 | $30,79338 claims |
| Astellas Pharma US IncMyrbetriq | $147 | $6,07723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Royersford
- Wade BrosiusRoyersford$180K
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.